Transcriptomic without Clinical Response to Menin Inhibition As a Mechanism of Upfront Resistance in Samples from Mutliply Relapsed Patients with KMT2A-Rearranged Leukemia

被引：0
|
作者：
Mahdavi, Leila [1 ]
Goodrow, Haley [1 ]
Xie, Hongbo [1 ]
Lenard, Alexandra [1 ]
Alikarami, Fatemeh [1 ]
Riedel, Simone Stefanie [1 ]
Tasian, Sarah K. [1 ]
Wertheim, Gerald [2 ]
Skuli, Sarah [3 ]
Carroll, Martin [4 ]
McGeehan, Jerry [5 ]
Bernt, Kathrin M. [6 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Pathol & Lab Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[5] Syndax, Waltham, MA USA
[6] Childrens Hosp Philadelphia, Pediat Oncol, Philadelphia, PA 19104 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180967
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 10 条
  • [1] Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
    Issa, Ghayas C.
    Aldoss, Ibrahim
    Thirman, Michael J.
    Dipersio, John
    Arellano, Martha
    Blachly, James S.
    Mannis, Gabriel N.
    Perl, Alexander
    Dickens, David S.
    Mcmahon, Christine M.
    Traer, Elie
    Zwaan, C. Michel
    Grove, Carolyn S.
    Stone, Richard
    Shami, Paul J.
    Mantzaris, Ioannis
    Greenwood, Matthew
    Shukla, Neerav
    Cuglievan, Branko
    Kovacsovics, Tibor
    Gu, Yu
    Bagley, Rebecca G.
    Madigan, Kate
    Chudnovsky, Yakov
    Nguyen, Huy Van
    Mcneer, Nicole
    Stein, Eytan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01)
  • [2] Decoding the Epigenetic Drivers of Menin-MLL Inhibitor Resistance in KMT2A-Rearranged Acute Myeloid Leukemia
    Zhou, Xinyue
    Zhang, Lixia
    Aryal, Sajesan
    Moreira, Steven
    Veasey, Virginia
    Hope, Kristin J.
    Lu, Rui
    BLOOD, 2023, 142
  • [3] Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia
    Adriaanse, Fabienne R. S.
    Schneider, Pauline
    Arentsen-Peters, Susan T. C. J. M.
    da Fonseca, Ana M. Neves
    Stutterheim, Janine
    Pieters, Rob
    Zwaan, C. Michel
    Stam, Ronald W.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [4] Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A-Rearranged RAS Pathway-Mutant Acute Leukemia
    Scheidegger, Nastassja
    Alexe, Gabriela
    Khalid, Delan
    Ries, Rhonda E.
    Wang, Jim
    Alonzo, Todd A.
    Perry, Jennifer
    Armstrong, Scott A.
    Meshinchi, Soheil
    Pikman, Yana
    Stegmaier, Kimberly
    BLOOD, 2023, 142
  • [5] The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia
    Ahlgren, Louise
    Pilheden, Mattias
    Sturesson, Helena
    Singh, Varsha
    Zhang, Qirui
    Castor, Anders
    Pronk, Cornelis Jan
    Barbany, Gisela
    Tamm, Katja Pokrovskaja
    Fogelstrand, Linda
    Walsh, Michael P.
    Song, Guangchun
    Zhang, Jinghui
    Ma, Jing
    Hagstroem-Andersson, Anna
    BLOOD, 2022, 140 : 9189 - 9190
  • [6] Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
    Ball, Brian J.
    Arslan, Shukaib
    Koller, Paul
    Ngo, Dat
    Afkhami, Michelle
    Salhotra, Amandeep
    Al-Malki, Monzr
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Otoukesh, Salman
    Amanam, Idoroenyi
    Pourhassan, Hoda
    Artz, Andrew
    Curtin, Peter
    Stein, Anthony
    Nakamura, Ryotaro
    Marcucci, Guido
    Smith, Eileen
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3232 - 3236
  • [7] Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic Leukemia Cells
    Schneider, Pauline
    Arentsen-Peters, Susan T. C. J. M.
    Crump, Nicholas T.
    Smith, Alastair
    Hagelaar, Rico
    Adriaanse, Fabienne R. S.
    Bos, Romy S.
    Vrenken, Kirsten S.
    Rockx-Brouwer, Dedeke
    Tang, Ziqin
    Vermeij, Wilbert P.
    De Jong, Anja
    Koopmans, Bianca
    Dolman, M. Emmy M.
    Milne, Thomas A.
    Pieters, Rob
    Stam, Ronald W.
    BLOOD, 2022, 140 : 8760 - 8761
  • [8] Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
    Schneider, Pauline
    Crump, Nicholas T.
    Arentsen-Peters, Susan T. C. J. M.
    Smith, Alastair L.
    Hagelaar, Rico
    Adriaanse, Fabienne R. S.
    Bos, Romy S.
    de Jong, Anja
    Nierkens, Stefan
    Koopmans, Bianca
    Milne, Thomas A.
    Pieters, Rob
    Stam, Ronald W.
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [9] Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia
    Pauline Schneider
    Nicholas T. Crump
    Susan T.C.J.M. Arentsen-Peters
    Alastair L. Smith
    Rico Hagelaar
    Fabienne R.S. Adriaanse
    Romy S. Bos
    Anja de Jong
    Stefan Nierkens
    Bianca Koopmans
    Thomas A. Milne
    Rob Pieters
    Ronald W. Stam
    Experimental Hematology & Oncology, 12
  • [10] Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
    Issa, Ghayas C.
    Cuglievan, Branko
    Stein, Eytan
    Arellano, Martha L.
    Zucenka, Andrius
    Khera, Nandita
    Stone, Richard M.
    Thirman, Michael J.
    DiPersio, John F.
    Karras, Nicole
    Gu, Yu
    Bagley, Rebecca G.
    Rosen, Galit
    Tamang, David
    Dishman, Kimberly
    Scalera, Sushama
    Meyers, Michael L.
    Madigan, Kate
    McNeer, Nicole
    Aldoss, Ibrahim
    BLOOD, 2022, 140
1